Decision criteria that influence managed entry agreements

3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties.  ...

Read more →

Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience

31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...

Read more →

The Australian Managed Entry Scheme: are we getting it right?

23 April 2018 - In 2010, the Australian Government introduced the managed entry scheme (MES) to improve patient access to subsidised ...

Read more →

A managed access approach to appraising new cancer drugs in England

12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...

Read more →

Characteristics of managed entry agreements in Australia

26 December 2017 - Australia relies on managed entry agreements for many medicines added to the national Pharmaceutical Benefits Scheme.  ...

Read more →

Managed entry agreements for oncology drugs: lessons from the European experience to inform the future

4 April 2017 - The aim of this study was to conduct an analysis on the regulation and application of ...

Read more →

Access to Medicines Working Group communiques

8 September 2016 - The communiques from the February 2015, September 2015 and April 2016 meetings of the Access to Medicines ...

Read more →

New “managed access” process for Cancer Drugs Fund to go ahead, NHS England confirms

29 February 2016 - NHS England has confirmed that from 1 July its Cancer Drugs Fund will operate on a “managed ...

Read more →